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Abstract

The foundational advancements of John Gurdon and Shinya Yamanaka have improved understanding of dedifferentiation of cells to a pluripotent state. The seminal discovery established a novel system to study disease pathogenesis,
drug screening, and toxicity, as well as sprouted the new field of regenerative medicine. In this article, the methodology to obtain dedifferentiated cells, known as induced pluripotent stem (iPS) cells, subsequent validation, and
application of which are reviewed. The experiments investigated here aim to demonstrate the capacity of iPS cells to
replace the ethically-gray human embryonic cells by developing human livers and viable, healthy animals. It is concluded that the reported methods pave the way for a bright future of iPS cell application in both basic and applied
sciences.

Introduction

Stem cells have immense
potential for treatment of diseases
including diabetes and heart disease through regenerative cell based
therapies1. As a result, the scientific
community has put forth tireless
effort to better understand these
cells and their unique capacity to
differentiate into the plethora of
cells observed in biological systems.
The undertaking began with basic
science experimentation where many
researchers turned to the ovum to
elucidate the beginning steps of cell
differentiation. John Gurdon, winner of the Nobel Prize in Physiology
or Medicine in 2012, was among
the first to investigate what changes
the somatic cell nucleus undergoes
during embryonic differentiation2.
After isolating recipient eggs and
tagging donor embryo nuclei from

Xenopus laevis, Gurdon exploited
the previously established nuclear
transplantation protocol to move the
tagged nuclei into the donor eggs.
Gurdon observed that some transplant frogs could grow to a normal
size, morphology, and have normal
reproductive function similar to
non-transplant frogs. From his work,
it was concluded that somatic cell
nuclei had all genes necessary for
normal developmental progression3.
Strelchenko took the same principle
of somatic cell nuclear transfer and
developed a novel technique that
fused a somatic cell with a human
embryonic stem (hES) cell. By
exploiting pre-existing factors in the
cytoplast of hES cells, Strelchenko
was able to culture cells harboring
the nuclear genome of the somatic
cell but had the differentiation capacity of hES cells4. Although amaz-

ing, both Gurdon and Strelchenko’s
work lack an understanding of the
factors associated with reverting a
somatic nuclei to one reminiscent of
an embryonic nuclei.

The Generation of iPS Cells

In a ground-breaking endeavor worthy of sharing the Nobel
Prize in Physiology or Medicine with
Gurdon in 2012, Shinya Yamanaka
of Kyoto University identified the
elusive factors necessary to induce
pluripotency5,6. To do this, Yamanaka developed a retrovirus containing
green fluorescent protein (GFP) and
four essential factors later coined the
Yamanaka cocktail: Oct3/4, Sox2,
Klf4, c-Myc. Adult human dermal
fibroblasts (HDF) that had previously been supplemented with artificial
mouse receptors for retrovirus were
then transfected using the previously
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developed retrovirus. Oct3/4 and
Sox2 are known to encode for transcription factors associated with the
developmentally critical homeodomain proteins as well as contribute
to pluripotency and self-renewal7.
Klf4 is a bona fide component of the
pre-transcriptional machinery for
Tert expression through interactions
with ß-catenin8. C-Myc is traditionally known to be a transcription
factor but has also been proven to
be responsible for promoting formation of euchromatin in the human
genome9. Six days after transfection,
Yamanaka and colleagues collected
cells via trypsinization and subsequently plated collected cells with
SNL feeder cells10.
The remaining majority
of the protocol implemented by
Yamanaka aimed to isolate and culture iPS cells. This started with first
growing cells in a medium containing 10% fetal bovine serum (FBS).
The medium was shortly thereafter
replaced with a medium designed
for primate ES cells supplemented
with basic fibroblast growth factor (bFGF). After a full month of
culturing, flat colonies resemblant
of hES colonies were isolated via
mechanic disaggregation and then
transferred to fresh primate ES cell
medium containing bFGF. At this
stage, individual cells and cell colonies displayed morphologic characteristics similar to hES cells; these
similarities include large nuclei with
little cytoplasm and aggregates that
formed in tightly packed flat colonies. In hES cell cultures, cells located in the center of aggregates tend to
differentiate. At this stage of experimentation, the same phenomenon
was observed in the hES-like cell
aggregates. To sustain the suspected
undifferentiated capacity of cells that
resembled hES, cells were transferred
to plates in mouse embryo fibroblast
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(MEF)-conditioned ES cell medium.
These cells were then tested for pluripotency and were then on referred
to as induced pluripotent stem (iPS)
cells. To confirm that iPS cells were
analogous to hES cells, Yamanaka
compared iPS cell similarity to hES
cells based on the following criteria:
morphology, proliferation, feeder
dependence, surface markers, gene
expression, promoter activities, telomerase activities, in-vitro differentiation to three different germ layers,
and teratoma formation. Yamanaka
also observed that transgenic genes
had been silenced by the time the
cell reached an hES-like state10.

Validation of iPSCs

Since the establishment of
the Yamanaka cocktail, researchers
hoped that iPS cells could replace
the ethically controversial ES cells
and set out to do so. Kristin Baldwin
of the Dorris Neuroscience Center
at Scripps Research Institute has
recently generated iPS-derived mice
to validate their candidacy to substitute for ES cells11,12. Baldwin used
the procedure developed by Yamanaka but added a method to control
expression of the Yamanaka cocktail
through a tetO promoter. The tetO
promoter is activated by a reverse
tetracycline transactivator (rtTA)
protein in the presence of tetracycline analogue doxycycline (dox).
In this way, Baldwin could drive
expression of the Yamanaka cocktail
with the addition of dox and rtTA.
Baldwin also exposed MEFs to a
histone deacetylase inhibitor valproic
acid (VPA) to enhance reprogramming efficiency and select against
incompletely reprogrammed cells by
restricting cellular division11.
After developing several iPS
cell lines, Baldwin strived to generate
an iPS-derived adult mouse. To do
so, Baldwin first conducted a tetra-

ploid complementation assay. This
was used to develop embryos with
an albino phenotype from each of
the iPS cell lines. This was accomplished by fusing the two cells of
an embryo at the two cell stage to
make one tetraploid cell. Normal
development can take place up to
blastocyst formation. At the blastocyst stage, the cell is anucleated and
fused with a diploid iPS cell that will
have an agouti phenotype11,13. The
agouti blastocysts were then injected into separate albino female mice
and pups were collected a day prior
to estimated delivery via Caesarean section. During early stages of
development, some pups from each
cells line were either cannibalized,
non-viable, or viable. All pups were
observed to have normal morphologies. Of the non-viable pups, most
presented with respiratory complications. Adult male iPS cell-derived
mice later demonstrated successful
reproductive capacity to produce viable offspring11. Although Baldwin’s
work provided an initial foundation
demonstrating that iPS cells had the
potential to replace ES cells, research
was still far from developing satisfactory results to initiate clinical studies.
Using Baldwin and Yamanaka’s concepts and techniques,
Hideki Taniguchi of Yokohama
City University in Japan set out to
demonstrate iPS cells are bona fide
substitutes of hES cells by creating a
human liver from an iPS cell organ
bud14. Taniguchi prepared hepatic
endoderm cells from human iPS
cells (iPSC-HEs). To mimic early
organogenesis of the liver, human
iPSC-HEs were grown in conjunction with a stromal cell population
to activate the FGF and BMP pathways. The stromal cell population
was composed of human umbilical
vein endothelial cells (HUVECs)

and urine samples collected from
mice transplanted with the human
iPSC-LBs, metabolites unique to a
human liver were found. Taniguchi
then assessed the metabolome for
metabolites of sugars, amino acids
and nucleotides. Of the 222 metabolites assessed, the metabolome bore
strong resemblance to a human adult
liver rather than human iPS cells.
In addition to its metabolic capability, the human iPSC-LB-derived
liver displayed full vascularization15.
This research validated iPS cells as
candidates for replacing ES cells and
paved the way for their application
in regenerative medicine.

Current Status of iPSC
Application

Masayo Takahashi of RIKEN
laboratory in Japan has recently
received government approval in
July 2013 for a pilot study using iPS
cell therapy in wet-type age-related
macular degeneration (AMD)16.
Although the cause of AMD is
unknown, the disease has been well
characterized. AMD patients present with an abnormal growth of new
blood vessels in the tissue proximal
to the eye. This abnormal growth
causes damage to the retinal pigment epithelium (RPE) and sensory
retina. Takahashi plans to collect a
biopsy of skin cells from each patient
to produce iPS cells unique to each
patient. The iPS cells can then be
differentiated to form a monolayer
cell culture of RPE. After surgically
removing damaged RPE and other
undesired growths, the missing
epithelium can be replaced by the
monolayer of iPS cell-derived RPE
cells. The initial treatment would
then be followed up by a one year
monitoring period and then a three
year period of follow up examinations. The current challenges for the
pilot study involve taking a biopsy

and inhibiting the formation of
tumors. Dr. Takahashi has thus far
approved six patients for treatment16.
The risks associated with Takahashi’s
pilot study may seem few, but there
are many experimental hurdles to
overcome prior to transplantation.
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and human mesenchymal stem cells
(MSCs). After 48 hours of plating,
the cell culture was observed to
self-organize into three dimensional
aggregates. These aggregates were
proven to be iPS cell-derived liver buds (iPSC-LBs) via antibody
staining. To see if the liver-bud
cells more closely resembled human
livers or human iPS cells derived
from mature hepatocyte-like cells,
Taniguchi implemented microarray
analysis to assess the expression of 83
genes known to be upregulated during liver development. Microarray
analysis showed that the liver-bud
cells resembled human livers 22-40
weeks into gestation. Qualitative
analysis with fluorescence-activated
cell sorting (FACS) indicated that
cells expressed proteins associated
with adult livers; these proteins
include the tight junction protein
zona occludens 1 (ZO1), ALB,
CK8/18, asialoglycoprotein receptor
1 (ASGR1), and collagen IV. Histologic examination revealed the presence of a hepatic cord-like structure
- a defining characteristic of adult
livers15.
After developing viable organ
buds, Hideki Taniguchi tested if the
iPSC-LBs had the capacity to generate fully functional livers. Using the
cranial window model, liver-buds
were transplanted and monitored.
Microarray analysis indicated that
human iPSC-LBs were more similar
to matured hepatocytes than iPSCMHs. Considering that hepatocytes
are the main cell of the liver tissue,
this provided an encouraging indicator that an iPSC-LB derived liver
had formed. To assess its functionality, mice with the human iPSC-LB
transplant were injected with either
ketoprofen or debrisoquine. Ketoprofen and debrisoquine are drugs
known to be metabolized differently
in humans than in mice. In serum

Current Issues and Future of
iPSCs

The problems faced with iPS
cell research stem from the recent
evolution of iPS cells and the consequent ambiguities of a system not
well characterized. For example, the
mechanism by which the Yamanaka
cocktail induces pluripotency is not
well understood. An understanding
of the signal transduction cascades
involved may resolve other issues
such as low iPS cell yield. In Yamanaka’s study, 5 x 104 fibroblasts
were used to yield roughly ten hES
cell-like colonies. The undesirably
low induction efficiency may be
due to one or a combination of the
following factors: low efficiency of
HDF transduction, mechanistic
difficulty teasing apart iPS cells from
differentiated cells, or the transfection integration site may be sitespecific at a loci10. Similar challenges
beget similar complications as Baldwin had found with her experimentation that had low yields for iPS
cell-derived mice. Baldwin reports
that 0.3-13% of iPS cells were able
to generate mice. Another problem
emerged as roughly 20% of viable
mice developed tumors resulting
from c-Myc reactivation11. The high
rate of tumor development could
also be attributed to the approximate
20 retroviral integration sites per
clone10. Due to the absence of reliable transplantation techniques for
therapeutic application, Taniguchi
also faced issues of low yield when
transplanting iPSC-LBs15. Not only
are iPS cells and iPS cell derivatives
88
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challenging to generate, they are
notidentical to hES cells. An ideal
candidate to substitute hES cells
would have high similarity in expression, morphology, and proliferation
capacity. Some differences have been
highlighted through microarray
analyses. Researchers have concluded that iPS cells are like ES cells
but are not ES cells10. Due to their
dissimilarity and difficulty to generate, many researchers have turned to
developing alternative techniques to
induce pluripotency.
Dr. Andrew Wan of the
Institute of Bioengineering and
Nanotechnology in Singapore is one
of many working on developing a
non-viral vector method to induce
pluripotency in somatic cells. Wan
has developed a protein delivery
system that requires the synthesis of
a long hydrocarbon chain with hydrophilic functional groups incorporated at both ends of the molecule;
this system is formerly known as a
cationic bolammphiphile protein
delivery system18. The delivered proteins are able to induce pluripotency
at low toxicity but also low yield.
Because this system requires the
synthesis of an intricate cationic bolaamphiphile complex, the technique
is challenging to some of the most
experienced scientists19. Currently,
the most reliable method to revert
cells back to an ES-like state relies
on the transfection of the Yamanaka
cocktail.

Closing Remarks

IPS cell cultures can replace
hES cells for understanding disease mechanisms, drug screening,
and toxicology10. Using Taniguchi’s
method of developing human livers in mice models, in vivo drug
screening can be performed to test
for harmful effects or metabolites.
Taniguchi’s experiment also validates
89

a discussion of using organ-bud
transplantation as an alternative
avenue for the generation of organs
when treating organ failure15. Since
iPS cells can be made from ordinary
fibroblasts, such iPS cells are unique
to the patient because they will
harbor the same nuclear genome as
the patient10. This allows for patient
specific cultures that, in principle,
should reduce or eliminate patient
transplant rejection. Though iPS
provides an optimistic future for
basic and applied science research,
further characterization is necessary.
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